Potential interaction between clorsulon and ivermectin for malaria vector control.
Hongsuwong T. et al, (2025), Med Vet Entomol
Pharmacometric and statistical considerations for dose optimization.
Chotsiri P. et al, (2024), CPT Pharmacometrics Syst Pharmacol
In-host modeling of dengue virus and non-structural protein 1 and the effects of ivermectin in patients with acute dengue fever.
Ding J. et al, (2024), CPT Pharmacometrics Syst Pharmacol
Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections.
Ding J. et al, (2024), CPT Pharmacometrics Syst Pharmacol
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS Med, 21
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
Wongnak P. et al, (2024), Lancet Infect Dis, 24, 953 - 963
Efficacy of ivermectin and its metabolites against Plasmodium falciparum liver stages in primary human hepatocytes.
Annamalai Subramani P. et al, (2024), Antimicrob Agents Chemother, 68
Determination of ivermectin in plasma and whole blood using LC-MS/MS
Kaewkhao N. et al, (2024), Wellcome Open Research, 9, 231 - 231
Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants
Banda CG. et al, (2024), British Journal of Clinical Pharmacology
Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination.
Nguyen Ngoc Pouplin J. et al, (2024), Malar J, 23
A pharmacokinetic randomised interventional study to optimise dihydroartemisinin-piperaquine dosing for malaria preventive treatment in Malawian infants: A protocol for the OPTIMAL study
Banda CG. et al, (2024), Wellcome Open Research, 9, 291 - 291
Population pharmacokinetics of primaquine and its metabolites in African males.
Chotsiri P. et al, (2024), Malar J, 23
Impact of ivermectin components on Anopheles dirus and Anopheles minimus mosquito survival.
Khemrattrakool P. et al, (2024), Parasit Vectors, 17
Safety, pharmacokinetics, and potential neurological interactions of ivermectin, tafenoquine, and chloroquine in Rhesus macaques.
Vanachayangkul P. et al, (2024), Antimicrob Agents Chemother
Population pharmacokinetic modelling of primaquine exposures in lactating women and breastfed infants.
Wattanakul T. et al, (2024), Nat Commun, 15
Comparison of lumefantrine, mefloquine, and piperaquine concentrations between capillary plasma and venous plasma samples in pregnant women with uncomplicated falciparum and vivax malaria.
Saito M. et al, (2024), Antimicrob Agents Chemother, 68
Determination of ivermectin in plasma and whole blood using LC-MS/MS
Kaewkhao N. et al, (2024), Wellcome Open Research, 9, 231 - 231
Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match.
Cokljat M. et al, (2024), BMJ Glob Health, 9
Medication adherence framework: A population-based pharmacokinetic approach and its application in antimalarial treatment assessments.
Ding J. et al, (2024), CPT Pharmacometrics Syst Pharmacol